Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy
Authors
Keywords
-
Journal
Communications Biology
Volume 4, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-02-24
DOI
10.1038/s42003-021-01813-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evolution of antibody immunity to SARS-CoV-2
- (2021) Christian Gaebler et al. NATURE
- Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
- (2021) Romina Libster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
- (2021) Michael J. Joyner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
- (2021) Jennifer M. Dan et al. SCIENCE
- Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2
- (2021) Romain Gasser et al. Cell Reports
- Treatment of COVID-19 Patients with Convalescent Plasma
- (2020) Eric Salazar et al. AMERICAN JOURNAL OF PATHOLOGY
- Reflection on passive immunotherapy in those who need most: some novel strategic arguments for obtaining safer therapeutic plasma or autologous antibodies from recovered COVID ‐19 infected patients
- (2020) F Lanza et al. BRITISH JOURNAL OF HAEMATOLOGY
- Interpreting Diagnostic Tests for SARS-CoV-2
- (2020) Nandini Sethuraman et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The convalescent sera option for containing COVID-19
- (2020) Arturo Casadevall et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
- (2020) Feng-Cai Zhu et al. LANCET
- Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial
- (2020) Cesare Perotti et al. HAEMATOLOGICA
- Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19
- (2020) Ling Li et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2020) Feng-Cai Zhu et al. LANCET
- Encouraging results from phase 1/2 COVID-19 vaccine trials
- (2020) Naor Bar-Zeev et al. LANCET
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- (2020) Pedro M Folegatti et al. LANCET
- A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction
- (2020) Chee Wah Tan et al. NATURE BIOTECHNOLOGY
- Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
- (2020) Quan-Xin Long et al. NATURE MEDICINE
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
- (2020) Lisa A. Jackson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike
- (2020) J. Seghatchian et al. TRANSFUSION AND APHERESIS SCIENCE
- A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization
- (2020) David Peterhoff et al. INFECTION
- SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
- (2020) Gregory A Poland et al. LANCET
- Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
- (2020) Anup Agarwal et al. BMJ-British Medical Journal
- Neutralizing Antibodies Against SARS-CoV-2—Important Questions, Unclear Answers
- (2020) Mitchell H. Katz JAMA Internal Medicine
- Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
- (2020) Wen Shi Lee et al. Nature Microbiology
- Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
- (2020) Jeffrey Seow et al. Nature Microbiology
- Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients
- (2020) Anita S. Iyer et al. Science Immunology
- Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors
- (2020) Cong Zeng et al. JCI Insight
- Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2
- (2020) Jéromine Klingler et al. JOURNAL OF INFECTIOUS DISEASES
- A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
- (2020) Ventura A. Simonovich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome
- (2020) Katharina Röltgen et al. Science Immunology
- Influenza Virus-Specific Neutralizing IgM Antibodies Persist for a Lifetime
- (2014) Ioanna Skountzou et al. Clinical and Vaccine Immunology
- IgM in microbial infections: Taken for granted?
- (2009) Rachael Racine et al. IMMUNOLOGY LETTERS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started